Patents by Inventor Alex Nivorozhkin

Alex Nivorozhkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250145566
    Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin receptor or monoamine transporter, such as inflammation, central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
    Type: Application
    Filed: February 15, 2023
    Publication date: May 8, 2025
    Applicant: Cybin IRL Limited
    Inventors: Alex Nivorozhkin, Joshua A. Hartsel, Clinton E. Canal, Francesco G. Salituro, Tina A. Mueller, Brett J. Greene, Alex Belser, Kenneth L. Avery, Amy Claire Reichelt, Geoffrey B. Varty, Michael Palfreyman
  • Patent number: 12291499
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: May 6, 2025
    Assignee: Cybin IRL Limited
    Inventor: Alex Nivorozhkin
  • Patent number: 12264141
    Abstract: The present invention is directed to methods of producing THC from CBD utilizing non-harsh methodology and resulting in substantially increased yields, as well as devices built upon these novel methods. The methods and devices are material efficient, and in certain embodiments, solvent-free. In particular, in certain embodiments, these methods and related devices are suitable for commercial production of THC from CBD. Furthermore, in certain embodiments, the present invention provides methods of producing THC from CBD in manner that affords tunability to select the ratio of THC-8 to THC-9.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: April 1, 2025
    Assignee: ARIELIUM HEALTH, LLC
    Inventor: Alex Nivorozhkin
  • Publication number: 20250082607
    Abstract: The present disclosure relates generally to methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.
    Type: Application
    Filed: February 27, 2024
    Publication date: March 13, 2025
    Applicant: Cybin IRL Limited
    Inventors: Alex Nivorozhkin, Michael Palfreyman, Pradip M. Pathare, Kenneth L. Avery, Mohammed I. Shukoor, Michael E. Morgan, Joan M. Krakowsky, Amir Inamdar, Pradeep J. Nathan, Sebastian Krempien
  • Patent number: 12240813
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: March 4, 2025
    Assignee: Cybin IRL Limited
    Inventors: Alex Nivorozhkin, Michael Palfreyman
  • Publication number: 20250051279
    Abstract: There are disclosed pharmaceutically acceptable salts of tryptamine compounds, the use of such salt forms in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as those adapted for inhalation administration containing the salt forms, methods of delivering the pharmaceutically acceptable salt forms (e.g., via inhalation), and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders, with the salt forms.
    Type: Application
    Filed: January 13, 2023
    Publication date: February 13, 2025
    Applicant: Cybin IRL Limited
    Inventors: Kenneth L. Avery, James He Huang, Alex Nivorozhkin, Pradip M. Pathare, Mohammed I. Shukoor
  • Publication number: 20250011282
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Application
    Filed: September 12, 2024
    Publication date: January 9, 2025
    Applicant: Cybin IRL Limited
    Inventors: Alex Nivorozhkin, Michael Palfreyman
  • Publication number: 20240425451
    Abstract: There are disclosed deuterated 2C—X phenethylamine compounds. the use of such compounds in the treatment of diseases associated with a serotonin 5-HIT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds. methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
    Type: Application
    Filed: September 5, 2024
    Publication date: December 26, 2024
    Applicant: Cybin IRL Limited
    Inventors: Alex Belser, Clinton E. Canal, Brett J. Greene, Joshua A. Hartsel, Alex Nivorozhkin, Michael Palfreyman
  • Publication number: 20240366655
    Abstract: Combination drag therapies comprising a 5-HTZA receptor agonist and an N-methyl-D-aspartate (NMDA) receptor antagonist (e.g., nitrous oxide, ketamine, etc.) are provided. Also described are pharmaceutical compositions and methods of treating a central nervous system (CNS) disorder or a psychiatric disease using the combination drug therapy, for example, via aerosol inhalation.
    Type: Application
    Filed: March 31, 2022
    Publication date: November 7, 2024
    Applicant: CYBIN IRL LIMITED
    Inventors: MICHAEL PALFREYMAN, ALEX NIVOROZHKIN, BRETT J. GREENE, ROBERT MINO
  • Patent number: 12122741
    Abstract: There are disclosed deuterated 2C—X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: October 22, 2024
    Assignee: Cybin IRL Limited
    Inventors: Alex Belser, Clinton E. Canal, Brett J. Greene, Joshua A. Hartsel, Alex Nivorozhkin, Michael Palfreyman
  • Patent number: 12110272
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: October 8, 2024
    Assignee: Cybin IRL Limited
    Inventors: Alex Nivorozhkin, Michael Palfreyman
  • Publication number: 20240317704
    Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.
    Type: Application
    Filed: August 18, 2021
    Publication date: September 26, 2024
    Applicant: CYBIN IRL LIMITED
    Inventors: Alex BELSER, Clinton E. CANAL, Brett J. GREENE, Joshua A. HARTSEL, Alex NIVOROZHKIN, Michael PALFREYMAN, Francesco SALITURO
  • Publication number: 20240293367
    Abstract: The present disclosure relates generally to methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.
    Type: Application
    Filed: February 27, 2024
    Publication date: September 5, 2024
    Applicant: Cybin IRL Limited
    Inventors: Alex Nivorozhkin, Michael Palfreyman, Pradip M. Pathare, Kenneth L. Avery, Mohammed I. Shukoor, Michael E. Morgan, Joan M. Krakowsky, Amir Inamdar, Pradeep J. Nathan, Sebastian Krempien
  • Publication number: 20240270691
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Application
    Filed: March 8, 2024
    Publication date: August 15, 2024
    Applicant: CYBIN IRL LIMITED
    Inventor: Alex Nivorozhkin
  • Publication number: 20240261306
    Abstract: The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 receptor. The pharmaceutical compositions are formulated with solid dispersions of psilocybin or deuterated psilocybin in amorphous form dispersed in a polymer.
    Type: Application
    Filed: May 17, 2022
    Publication date: August 8, 2024
    Applicant: CYBIN IRL LIMITED
    Inventors: ALEX NIVOROZHKIN, MICHAEL PALFREYMAN, KENNETH L. AVERY, PRADIP M. PATHARE, MOHAMMED I. SHUKOOR
  • Publication number: 20240174607
    Abstract: The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.
    Type: Application
    Filed: March 17, 2022
    Publication date: May 30, 2024
    Applicant: Cybin IRL Limited
    Inventors: Alex Nivorozhkin, Michael Palfreyman, Pradip Pathare, Kenneth L. Avery, Mohammed Shukoor, James He Huang, Michael E. Morgan, Joan M. Krakowsky
  • Patent number: 11958807
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Grant
    Filed: October 24, 2023
    Date of Patent: April 16, 2024
    Assignee: Cybin IRL Limited
    Inventor: Alex Nivorozhkin
  • Publication number: 20240067605
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Applicant: CYBIN IRL LIMITED
    Inventors: Alex Nivorozhkin, Michael Palfreyman
  • Patent number: 11834410
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: December 5, 2023
    Assignee: Cybin IRL Limited
    Inventors: Alex Nivorozhkin, Michael Palfreyman
  • Publication number: 20230357147
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Application
    Filed: July 17, 2023
    Publication date: November 9, 2023
    Applicant: CYBIN IRL LIMITED
    Inventors: Alex Nivorozhkin, Michael Palfreyman